Chitosan Oligosaccharide Modified Bovine Serum Albumin Nanoparticles for Improving Oral Bioavailability of Naringenin

• Published in: Current drug delivery
• Main Authors: Fang, Ruiyue, Liao, Yiqi, Qiu, Huishuang, Liu, Yuxin, Lin, Shiyuan, Chen, Hui
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2024
• Subjects: nanoparticle; Naringenin; bioavailability; chitosan oligosaccharide; bovine serum albumin; oral absorption
• ISSN: 1875-5704
• DOI: 10.2174/1567201820666230718143726

With the rapid development of nanotechnology, the research and development of nano-drugs have become one of the development directions of drug innovation. The encapsulation of the nanoparticles can change the biological distribution of the drug in vivo and improve the bioavailability of the drug in vivo. Naringenin is poorly soluble in water and has a low bioavailability, thus limiting its clinical application. The main purpose of this study was to develop a nano-sized preparation that could improve the oral bioavailability of naringenin. Chitosan oligosaccharide modified naringenin-loaded bovine serum albumin nanoparticles (BSA-COS@Nar NPs) were prepared by emulsification solvent evaporation and electrostatic interaction. The nanoparticles were characterized by HPLC, laser particle size analyzer, transmission electron microscope and X-ray diffraction analysis. The release in vitro was investigated, and the behavior of nanoparticles in rats was also studied. The caco-2 cell model was established in vitro to investigate the cytotoxicity and cellular uptake of nanoparticles. BSA-COS@Nar NPs were successfully prepared, and the first-order release model was confirmed in vitro release. In vivo pharmacokinetic results indicated that the area under the drug concentration-time curve (AUC) of BSA-COS@Nar NPs was 2.37 times more than free naringenin. Cytotoxicity and cellular uptake results showed that BSA-COS@Nar NPs had no significant cytotoxic effect on Caco-2 cells and promoted cellular uptake of the drug. BSA-COS@Nar NPs could improve the in vivo bioavailability of naringenin.